Novogenia AG

As of December 31, 2025, Novogenia AG carries a market capitalization of 92.40M, placing it among publicly traded companies globally. Its enterprise value stands at 45.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novogenia AG's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Novogenia AG has 12.00M shares outstanding.

As of December 31, 2025, Novogenia AG trades at a trailing price-to-earnings ratio of 154.00. The price-to-sales ratio is 1.55, and the price-to-book ratio stands at 0.92.

These figures are as of December 31, 2025. The EV/Sales ratio of 0.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 45.46M versus a market cap of 92.40M, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, Novogenia AG maintains a current ratio of 5.81, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.15, indicating elevated leverage, while an interest coverage ratio of -12.56 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Novogenia AG posted a return on equity (ROE) of 0.53, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -2.66, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.40, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.64, useful for judging operating efficiency across full business cycles. Inventory turnover of 4.01 indicates how many times Novogenia AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Novogenia AG recorded 1.50M in income tax expense. That works out to an effective tax rate of 73.31, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.04M, leaving 545,465.07 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novogenia AG's stock has declined approximately 8.72% over the past 52 weeks. The 50-day moving average sits at 6.66, while the 200-day moving average is 7.62.

Over the twelve months ended December 31, 2025, Novogenia AG generated 54.30M in revenue and converted that into 545,465.07 in net income, yielding earnings per share of 0.05. EBITDA reached -6.88M, while operating income came in at -10.78M.

As of December 31, 2025, Novogenia AG holds 53.02M in cash and equivalents against 6.15M in total debt, resulting in a net debt position of -6.38M. Total book value stands at 100.16M, with working capital of 62.79M providing operational flexibility.

Novogenia AG produced -12.97M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -8.67M in capital expenditures, free cash flow totaled -21.65M - equivalent to -1.98 per share.

Over the twelve months ended December 31, 2025, Novogenia AG posted a gross margin of 33.84, reflecting its pricing power and cost economics. The operating margin of -19.85 and net profit margin of 1.00 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, Novogenia AG paid dividends of 0.33 per share. The dividend payout ratio of 656.25 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -25.77: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 1.29, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Novogenia AG shareholders.

Novogenia AG's most recent stock split took place on September 18, 2025 with a 1:4 split ratio.

As of December 31, 2025, Novogenia AG has an Altman Z-Score of 4.71, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.